Patient-specific neoantigen-major histocompatibility complex (NeoAg-MHC) (NeoAg-MHC)

Patient-specific neoantigen-major histocompatibility complex (NeoAg-MHC) targets represent a cornerstone of personalized cancer immunotherapy. These complexes consist of unique peptides derived from tumor-specific somatic mutations—such as non-synonymous single nucleotide variants, insertions/deletions, or frameshifts—that are processed and presented on the cell surface by MHC Class I or Class II molecules (Xie et al., 2021, Nature). Because these neoantigens are not encoded by the normal genome, they are recognized as "foreign" by the immune system, bypassing central thymic tolerance and reducing the risk of autoimmune toxicity (Sahin & Türeci, 2018, Science). MHC Class I-bound neoantigens are primarily recognized by CD8+ cytotoxic T cells, leading to direct tumor cell lysis, while MHC Class II-bound neoantigens activate CD4+ helper T cells, which provide essential support for a sustained immune response (Hu et al., 2021, Journal of Hematology & Oncology). Therapeutic strategies targeting these complexes include personalized mRNA or peptide vaccines, which prime the immune system to recognize these specific "non-self" signatures (Blass & Ott, 2021, Nature Reviews Clinical Oncology). Additionally, adoptive cell therapies, such as TCR-engineered T cells, are designed to bind directly to these neoantigen-MHC complexes to induce tumor lysis. Despite their potential, challenges remain regarding the accurate prediction of which mutations will produce immunogenic neoantigens and the logistical hurdles of manufacturing individualized treatments (Aldous & Knecht, 2021, Frontiers in Immunology).

Other names

Tumor-specific neoepitopesNeoantigen-HLA complexesPersonalized tumor antigensSomatic mutation-derived antigensTSA-MHC complexes

Induction of de novo T-cell responses or expansion of existing neoantigen-specific T-cells (CD8+ and CD4+) to selectively eliminate tumor cells expressing the specific peptide-MHC complex.